TB-500
Thymosin-β4 fragment (17–23)
TB-500 is a commercially marketed synthetic fragment of thymosin beta-4. Studies of full-length thymosin beta-4 do not prove efficacy or dosing for TB-500.
Peptipedia explains research and prescribing information. It does not replace medical advice and is not an invitation to use a substance.
Identity not confirmed
The name may refer to different substance or product forms.
TB-500 is discussed here as the thymosin-beta-4 fragment LKKTETQ; a marketed product requires confirmation of sequence, acetylation and salt. It is not full-length thymosin-beta-4.
Research areas
Evidence matrix
- Molecular identity
- Partially clarified
TB-500 is discussed here as the thymosin-beta-4 fragment LKKTETQ; a marketed product requires confirmation of sequence, acetylation and salt. It is not full-length thymosin-beta-4.
- Human research
- None
- Replication
- No independent replication
- Clinical endpoints
- No clinical endpoints
- Safety
- Not adequately studied
- Approval
- No documented approval
The dimensions are presented separately and are not combined into an overall score.
Important distinction
The TB-500 fragment and full-length thymosin beta-4 are not the same investigational substance.
- FDA: Safety risks associated with thymosin beta-4 fragment in compoundingRegulatory source2024
U.S. Food and Drug Administration
Accessed:
- Thymosin beta 4 treatment of patients with venous stasis ulcersHuman study2010
U.S. National Library of Medicine (PubMed)
Accessed:
Research gaps
- ·FDA found no human exposure data for the evaluated fragment
- ·No reliable clinical efficacy or dose
- ·Full-length thymosin beta-4 studies are not transferable
Mechanism
A clinically confirmed mechanism of action has not been established for the TB-500 fragment described here. Findings for full-length thymosin beta-4 must not automatically be transferred to the fragment.
- FDA: Safety risks associated with thymosin beta-4 fragment in compoundingRegulatory source2024
U.S. Food and Drug Administration
Accessed:
Study protocols
No sufficiently supported, exactly citable study protocols are available.
Calculator
Arithmetic based only on your entries. Not a dose or use recommendation.
Reported adverse effects
- ·The fragment lacks adequate human safety data; immunogenicity and impurities remain concerns.
Contraindications and warnings
- ·Contraindications cannot be determined reliably because human studies are unavailable.
Interactions
- ·Interactions for the research or product forms described here have not been adequately studied.
Research gaps
- ·FDA found no human exposure data for the evaluated fragment
- ·No reliable clinical efficacy or dose
- ·Full-length thymosin beta-4 studies are not transferable
- FDA: Safety risks associated with thymosin beta-4 fragment in compoundingRegulatory source2024
U.S. Food and Drug Administration
Accessed:
Sources
Sources checked: · Version 2
- FDA: Safety risks associated with thymosin beta-4 fragment in compoundingRegulatory source2024
U.S. Food and Drug Administration
Accessed:
- Thymosin beta 4 treatment of patients with venous stasis ulcersHuman study2010
U.S. National Library of Medicine (PubMed)
Accessed: